Long term follow-up of a multicentre cohort of COVID-19 patients with pulmonary embolism: Anticoagulation management and outcomes

Pulmonary embolism (PE) is a frequent complication in COVID19 hospitalized patients. Inflammatory storm and endothelial dysfunction due to the virus seem to be the two major risk factors for PE. Consequently, PE related to COVID19 could be consider as triggered by a transient inflammatory acute phase and treated for no longer than 3  months. However, few data are available on management of anticoagulation and risk of venous thromboembolic (VTE) recurrences in these patients and guidelines are still undefined.

Source: Thrombosis Research - June 23, 2023 Category: Hematology Authors: Lucia Filippi, Gianni Turcato, Marta Milan, Sofia Barbar, Eliana Miozzo, Arian Zaboli, Diego Tonello, Daniela Milazzo, Massimo Marchetti, Stefano Cuppini, Paolo Prandoni Tags: Full Length Article Source Type: research